ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Patient views on blood-based biomarker tests for Alzheimer's disease in primary care.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionBlood-based biomarkers could offer accessible, cost-effective detection of Alzheimer's disease (AD) in primary care. This study examined patient attitudes toward AD biomarker testing.
methodsCrosssectional surveys were conducted with 572 adults from Chicago-area clinics. Participants received brief education on biomarker tests before completing the survey.
resultsMost participants (83.8%) were unfamiliar with biomarker tests; 1.8% previously completed testing. After brief education, most (94.5%) supported offering tests to patients with memory complaints, and 85% were willing to complete testing if recommended by their clinician. Facilitators included tests informing clinical care, coverage by insurance, and education in advance. Barriers included cost and reliability concerns. Participants commonly expected they would experience emotional distress and motivation to improve brain health after a positive test. DISCUSSION: Primary care patients educated about biomarker testing were generally willing to undergo testing and support its use. After a positive result, informational and psychological support may be needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.